摘要
目的回顾性分析复方泽桑汤联合胸腺肽治疗系统性硬皮病66例的临床疗效。方法评估复方泽桑汤联合胸腺肽治疗系统性硬皮病66例半年后的疗效。结果痊愈18例(27.3%),显效24例(36.4%),好转20例(30.3%),无效4例(6.1%),有效率为63.64%(42/66)。结论复方泽桑汤联合胸腺肽治疗系统性硬皮病疗效显著。
Objective To investigate the effect of Zesang polypharmacy combined with thymic peptide in treating systemic scleroderma（SSc）.Methods 66 patients with SSc were treated with Zesang polypharmacy and thymic peptide for half a year,and than the score was measured to evaluate the treatment effect.Results The effective rate of combined treatment was 63.64%（42/66）.Conclusion Zesang polypharmacy combined with thymic peptide seems to be effective in treating systemic scleroderma.
出处
《中国中西医结合皮肤性病学杂志》
CAS
2012年第2期106-107,共2页
Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine
关键词
复方泽桑汤
胸腺肽
系统性硬皮病
Zesang polypharmacy
thymic peptide
systemic scleroderma
